Clinical Trial Update: Lipiodol as an Imaging Biomarker in Patients With Primary and Metastatic Liver Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating Lipiodol as an imaging biomarker in patients with primary and metastatic liver cancer has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Liver Cancer

Drugs mentioned

• Lipiodol (Ethiodized oil)

Snippet

Sponsor: Yale University | Conditions: Liver Cancer | Phase 2 | Status: COMPLETED | Results posted: 2020-04-15